Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone
- 30 April 2003
- journal article
- clinical trial
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (2), 270-274
- https://doi.org/10.1053/sonc.2003.50044
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s MacroglobulinemiaJournal of Immunotherapy, 2001
- Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade GliomasJournal of Clinical Oncology, 2000
- Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancerBritish Journal of Cancer, 2000
- Waldenström’s Macroglobulinemia: Clinical Features, Complications, and ManagementJournal of Clinical Oncology, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenström's Macroglobulinemia, and Mantle-Cell LymphomaJournal of Clinical Oncology, 1999
- Waldenström's macroglobulinemia*Cancer, 1998
- First-line treatment of Waldenström's disease with cladribineAnnals of Hematology, 1997
- Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.Journal of Clinical Oncology, 1994
- The Spectrum of IgM Monoclonal Gammopathy in 430 CasesMayo Clinic Proceedings, 1987